PR Newswire - Celltrion USA announces two-year data for ZYMFENTR...
Data presentations including the extended LIBERTY studies to highlight the long-term treatment goals of ZYMFENTRA™, the first and only FDA-approved subcutaneous infliximab ...
Read More

ภาษาไทย
English